SCY_3392 Antibody

What is SCY_3392 Antibody and what organism does it target?

SCY_3392 Antibody (Product Code: CSB-PA413877XA01STA) is a polyclonal antibody that specifically targets the SCY_3392 protein (UniProt ID: A6ZZY2) from Saccharomyces cerevisiae strain YJM789, commonly known as Baker's yeast. This antibody is raised in rabbits using recombinant SCY_3392 protein as the immunogen. The antibody is primarily designed for research applications in yeast biology and is purified using antigen affinity methods to ensure specificity .

What are the recommended storage conditions for SCY_3392 Antibody?

SCY_3392 Antibody should be stored at either -20°C or -80°C upon receipt. It's important to avoid repeated freeze-thaw cycles as these can damage antibody structure and function. The antibody is supplied in liquid form in a storage buffer containing 0.03% Proclin 300 as a preservative, 50% glycerol, and 0.01M PBS at pH 7.4. These components help maintain antibody stability during storage. For short-term use during experiments, temporary storage at 4°C is acceptable, but return to freezer conditions is recommended for long-term preservation of antibody activity .

What applications has SCY_3392 Antibody been validated for?

SCY_3392 Antibody has been specifically tested and validated for Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blotting (WB) applications. These techniques allow researchers to detect and quantify the target protein in various experimental contexts. For Western Blotting, the antibody enables identification of the antigen based on molecular weight separation. While these are the validated applications, researchers may need to optimize conditions when applying this antibody to other immunological techniques such as immunoprecipitation or immunohistochemistry, as cross-application validation is not explicitly provided in the product specifications .

How should I determine the optimal working dilution of SCY_3392 Antibody for my specific application?

Determining the optimal working dilution of SCY_3392 Antibody requires systematic titration experiments. Start with the manufacturer's recommended range, typically 1:500 to 1:2000 for Western blotting and 1:1000 to 1:5000 for ELISA. Prepare a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000) and test against both positive controls (samples known to contain the target) and negative controls (samples lacking the target). Evaluate signal-to-noise ratio at each dilution, looking for the concentration that provides maximal specific signal with minimal background. For Western blotting, consider performing a dot blot titration before committing to full-size gels. Document the optimal conditions thoroughly as they may need to be adjusted when working with different sample types or detection systems .

What controls should be included when using SCY_3392 Antibody in experimental protocols?

A robust experimental design using SCY_3392 Antibody requires multiple controls. Essential controls include: (1) Positive control: A sample known to express SCY_3392 protein, ideally from the Saccharomyces cerevisiae YJM789 strain; (2) Negative control: Samples from organisms or cell types that do not express the target protein; (3) Secondary antibody-only control: Omitting the primary antibody to assess non-specific binding of the detection system; (4) Blocking peptide control: Pre-incubating the antibody with excess target peptide to demonstrate binding specificity; (5) Loading/housekeeping controls: To normalize for total protein content across samples. For advanced applications, consider isotype controls or SCY_3392 knockout/knockdown samples if available. These controls help distinguish specific signals from artifacts and provide confidence in experimental results .

How can I validate the specificity of SCY_3392 Antibody for my yeast strain of interest?

Validating SCY_3392 Antibody specificity for different yeast strains requires a multi-faceted approach. Begin with comparative Western blotting using protein extracts from your strain of interest alongside the YJM789 strain (for which the antibody was designed). Look for bands of the expected molecular weight and compare intensities. If possible, include a negative control strain with known absence of the target. For greater confidence, perform immunoprecipitation followed by mass spectrometry to confirm the identity of the pulled-down proteins. Consider creating a strain with tagged SCY_3392 and compare detection patterns between the antibody and tag-specific antibodies. If available, SCY_3392 knockouts provide excellent negative controls to demonstrate specificity. Cross-reactivity with homologous proteins in related strains may occur and should be evaluated, especially when working with non-YJM789 strains .

How can I use deep mutational scanning approaches with SCY_3392 Antibody to map epitope specificity?

Deep mutational scanning with SCY_3392 Antibody involves systematically assessing how mutations in the target protein affect antibody binding. First, generate a comprehensive mutant library of the SCY_3392 protein using techniques like error-prone PCR or saturation mutagenesis. Display these mutants on yeast cell surfaces using established display vectors. Incubate the yeast library with fluorescently labeled SCY_3392 Antibody and use fluorescence-activated cell sorting (FACS) to separate populations based on binding strength. Deep sequence the pre-sort and post-sort populations to identify mutations that affect antibody binding. This approach generates a comprehensive epitope map by identifying specific amino acid positions critical for antibody recognition. Analysis can reveal binding hotspots and tolerant regions, providing insights into antibody specificity and potentially guiding the development of more specific variants for particular experimental applications .

How can biophysics-informed modeling enhance the application of SCY_3392 Antibody in targeted research?

Biophysics-informed modeling can significantly enhance SCY_3392 Antibody research by predicting binding characteristics and designing experiments for optimal results. Begin by using available structural data or homology models of the SCY_3392 protein to predict epitope regions. Apply molecular dynamics simulations to evaluate the conformational states of these epitopes and assess their accessibility to the antibody. Using computational docking, predict the antibody-antigen binding interface and key interaction residues. These models can inform experimental design by suggesting optimal buffer conditions that maintain epitope structure, predicting cross-reactivity with related proteins, and identifying potential competitive inhibitors. For advanced applications, the models can guide the design of modified versions of the antibody with enhanced specificity or affinity through targeted mutations in the complementarity-determining regions (CDRs). This computational approach helps maximize experimental efficiency by focusing wet-lab efforts on high-probability success conditions .

What strategies can be employed to customize SCY_3392 Antibody specificity for distinguishing between closely related yeast proteins?

Customizing SCY_3392 Antibody specificity requires sophisticated antibody engineering approaches. Begin with epitope mapping to identify binding regions using techniques like hydrogen-deuterium exchange mass spectrometry or the deep mutational scanning described previously. Once binding epitopes are characterized, employ negative selection strategies through phage display to deplete antibodies that bind to unwanted targets while retaining those specific to SCY_3392. This involves iterative rounds of selection against related proteins to remove cross-reactive antibodies. For more precise customization, apply computational design methods that model the energetics of antibody-antigen interactions to predict mutations that would enhance binding to unique epitopes on SCY_3392 while reducing affinity for homologous regions in related proteins. These computational predictions can be validated through directed evolution experiments, creating antibody variants with custom specificity profiles tailored to distinguish SCY_3392 from its closest structural homologs in various yeast strains .

How can SCY_3392 Antibody be used in multiplexed detection systems for systems biology applications?

Implementing SCY_3392 Antibody in multiplexed detection systems enables simultaneous monitoring of multiple proteins within yeast cellular networks. For antibody-based multiplexing, conjugate SCY_3392 Antibody with a specific fluorophore, quantum dot, or mass tag that has a unique spectral or mass signature distinct from other antibodies in your panel. Alternatively, use secondary antibodies raised in different host species for each primary antibody in your panel. Advanced multiplexing can be achieved through sequential elution and re-probing of membranes or tissue sections, with SCY_3392 Antibody included in one of the probing rounds. For single-cell applications, consider mass cytometry (CyTOF) by labeling the antibody with isotopically pure metals. When analyzing data from multiplexed experiments, employ computational approaches to deconvolute signals and account for potential antibody cross-reactivity. These multiplexed approaches allow researchers to study SCY_3392 in the context of broader protein networks, providing insights into its functional relationships within yeast cellular systems .

What are the most common causes of high background when using SCY_3392 Antibody in immunoassays?

High background with SCY_3392 Antibody can result from multiple factors requiring systematic troubleshooting. Insufficient blocking is often the primary cause; increase blocking agent concentration (typically to 5% BSA or milk) and extend blocking time to 2 hours at room temperature. Non-specific binding can occur if the antibody concentration is too high; try more dilute antibody preparations, starting with a 2-5 fold higher dilution than previously used. The wash protocol may be inadequate; implement more stringent washing with increased duration, volume, and number of wash steps using buffers containing 0.1-0.3% Tween-20. The secondary antibody might contribute to background; test different secondary antibodies or increase their dilution. Sample preparation issues, including incomplete protein denaturation or the presence of endogenous peroxidases/phosphatases, can elevate background; optimize sample preparation protocols and include appropriate inhibitors. Finally, the storage buffer components (particularly the 50% glycerol) may cause issues in some applications; dialysis against PBS might be beneficial in sensitive applications .

How can I resolve inconsistent Western blot results when using SCY_3392 Antibody across different experiments?

Resolving inconsistent Western blotting results with SCY_3392 Antibody requires systematic standardization of protocols. First, establish consistency in sample preparation by standardizing cell lysis methods, protein extraction buffers, and protein quantification techniques. Implement a rigorous quality control process for the antibody itself, including regular validation using positive controls and aliquoting to avoid freeze-thaw cycles. Standardize gel electrophoresis parameters, including acrylamide percentage, running buffer composition, and transfer conditions. For the immunoblotting step, prepare fresh antibody dilutions from master stocks, maintain consistent incubation times and temperatures, and use automated washing systems if available. Document all experimental parameters meticulously, including batch numbers of reagents, exact timings, and equipment settings. Consider using internal loading controls and normalization standards consistently across experiments. For challenging targets, explore alternative detection systems or signal amplification methods. Finally, implement quantitative analysis using digital imaging and densitometry with appropriate statistical treatments to objectively assess variability between experimental replicates .

How can I reconcile contradictory results between SCY_3392 Antibody detection and RNA expression data for the target gene?

Reconciling contradictory results between SCY_3392 Antibody protein detection and RNA expression requires systematic investigation of several biological and technical factors. First, conduct time-course experiments to examine potential temporal delays between transcription and translation, as post-transcriptional regulation may cause offset patterns between mRNA and protein levels. Assess protein stability through cycloheximide chase experiments to determine if the protein has an unusually long or short half-life compared to its mRNA. Investigate post-transcriptional regulatory mechanisms like RNA sequestration, miRNA regulation, or RNA binding proteins that might inhibit translation of the target mRNA. Examine potential technical artifacts in both detection methods: for RNA measurements, verify primer specificity and RNA quality; for protein detection, ensure the antibody recognizes all protein isoforms and is not affected by post-translational modifications that might mask epitopes. Consider subcellular localization differences that might affect extraction efficiency for protein assays. When possible, employ absolute quantification methods for both RNA (using spike-in standards) and protein (using recombinant standards) to enable direct numerical comparisons. These systematic approaches can help identify the biological basis for apparent discrepancies between transcript and protein levels .

How might custom modifications of SCY_3392 Antibody enhance its application in super-resolution microscopy techniques?

Custom modifications of SCY_3392 Antibody for super-resolution microscopy would focus on optimizing signal properties and spatial precision. Direct conjugation with photo-switchable fluorophores like Alexa Fluor 647 or photoinducible dyes enables techniques like STORM (Stochastic Optical Reconstruction Microscopy) and PALM (Photoactivated Localization Microscopy), achieving ~20nm resolution. For STED (Stimulated Emission Depletion) microscopy, conjugation with STED-optimized dyes such as ATTO 647N or Abberior STAR RED would be advantageous. Fragment antibody technologies, particularly generating Fab fragments through enzymatic digestion with papain, can reduce the effective size of the detection complex from ~15nm to ~5nm, significantly improving spatial resolution. Site-specific labeling through engineered cysteine residues or sortase-mediated conjugation would ensure consistent dye positioning and optimal fluorophore performance. For multi-color imaging, carefully selected fluorophore combinations with minimal spectral overlap are essential. Additionally, incorporating click chemistry handles enables secondary labeling strategies that can enhance signal without increasing the size of the detection complex. These modifications would transform SCY_3392 Antibody into a powerful tool for visualizing the nanoscale organization and dynamics of its target protein in yeast cells .

What emerging computational approaches could enhance the design of next-generation SCY_3392 Antibody variants with improved specificity profiles?

Emerging computational approaches offer transformative potential for designing next-generation SCY_3392 Antibody variants with enhanced specificity. Deep learning algorithms trained on antibody-antigen co-crystal structures can now predict binding interfaces and energetics with unprecedented accuracy. These models integrate evolutionary sequence information, structural predictions, and physicochemical properties to identify optimal binding configurations. Machine learning-guided directed evolution strategies can efficiently navigate the vast sequence space by predicting mutations likely to improve specificity based on initial experimental data. Molecular dynamics simulations with explicit solvent models provide insights into the dynamic nature of antibody-antigen interactions, revealing transient binding states that affect specificity. Graph neural networks are increasingly used to model the complex network of interactions within antibody-antigen complexes, enabling rational design of mutations that selectively enhance desired interactions while disrupting unwanted ones. Negative design principles, which explicitly model non-target interactions to minimize them, are particularly valuable for enhancing discrimination between closely related epitopes. Integration of these computational approaches with high-throughput experimental validation creates an iterative design-build-test cycle that can rapidly converge on antibody variants with customized specificity profiles optimized for distinguishing SCY_3392 from structurally similar yeast proteins .

What is the recommended workflow for first-time users of SCY_3392 Antibody in yeast research?

For first-time users of SCY_3392 Antibody, a structured workflow ensures successful implementation in yeast research. Begin with antibody validation by performing Western blot analysis on positive control samples (Saccharomyces cerevisiae strain YJM789) alongside negative controls and your samples of interest. Test a dilution series (1:500, 1:1000, 1:2000) to determine optimal antibody concentration for your specific application. For yeast sample preparation, optimize cell wall disruption using either mechanical methods (glass bead beating) or enzymatic approaches (zymolyase treatment) to ensure adequate protein extraction while maintaining epitope integrity. Include proper controls in all experiments: positive and negative sample controls, technical replicates, and secondary antibody-only controls to assess background. Document all experimental parameters meticulously, including incubation times, temperatures, buffer compositions, and washing protocols. Start with the most robustly validated application (Western blotting) before moving to more complex applications like immunoprecipitation or immunofluorescence. For quantitative applications, establish standard curves using recombinant protein if available. This systematic approach maximizes the likelihood of generating reliable, reproducible results while identifying any application-specific optimizations required for your particular experimental system .

What comprehensive data should be included when reporting research results using SCY_3392 Antibody in publications?

Comprehensive reporting of SCY_3392 Antibody usage in publications should include detailed methodology and validation data to ensure reproducibility. Start with complete antibody identification: manufacturer (Cusabio), catalog number (CSB-PA413877XA01STA), lot number, and RRID (Research Resource Identifier) if available. Document validation steps performed, including Western blot images showing single bands of expected molecular weight, positive and negative controls used, and any orthogonal validation approaches employed (e.g., correlation with tagged protein variants). Provide explicit experimental details: antibody dilution (1:xxxx), incubation conditions (time, temperature, buffer composition), washing protocols, blocking reagents, and detection methods. For quantitative applications, report normalization approaches, standard curves, and statistical analyses. Include images of full, unprocessed blots or micrographs with molecular weight markers visible and scale bars on microscopy images. Disclose any image processing performed and use appropriate statistical analyses for quantifications. Address antibody specificity limitations, particularly when working with non-YJM789 yeast strains. This comprehensive reporting enables proper evaluation of results and facilitates reproduction by other researchers, adhering to emerging standards for antibody-based research in the scientific community .